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Background: Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired
infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries.
Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical
treatment of choice for VAP is unknown. Colistin, is now the antimicrobial with greatest in vitro activity against MDR-GNB.
Methods/Design: The MagicBullet clinical trial is an investigator-driven clinical study, funded by the Seventh Framework
Program of the European Commission. This is designed as a phase IV, randomized, controlled, open label, non-inferiority
and international trial to assess the safety and efficacy of colistin versus meropenem in late onset VAP. The study is
conducted in a total of 32 centers in three European countries (Spain, Italy and Greece) with specific high incidences of
infections caused by MDR-GNB. Patients older than 18 years who develop VAP with both clinical and radiological signs, and
are on mechanical ventilation for more than 96 hours, or less than 96 hours but with previous antibiotic treatment plus
one week of hospitalization, are candidates for inclusion in the study.
A total sample size of 496 patients will be randomized according to a severity clinical score (at the time of VAP diagnosis in
a 1:1 ratio to receive either colistin 4.5 MU as a loading dose, followed by 3 MU every eight hours (experimental arm), or
meropenem 2 g every eight hours (control arm), both combined with levofloxacin. Mortality from any cause at 28 days will
be considered as the main outcome. Clinical and microbiological cure will be evaluated at 72 hours, eight days, the
finalization of antibiotic treatment, and 28 days of follow-up. The efficacy evaluation will be performed in every patient who
receives at least one study treatment drug, and with etiologic diagnosis of VAP, intention-to-treat population and per
protocol analysis will be performed.
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Discussion: Currently, there is no study being undertaken which analyzes empiric treatment of (VAP) with a suspicion of
multi-resistance. Colistin, an off-patent antibiotic commercialized for more than 60 years, could widen the antibiotic
alternatives for a high-mortality illness aggravated by antibiotic resistance.
Trial registration: This trial is registered with ClinicalTrials.gov (identifier: NCT01292031; registered on 29 June 2012) and
EudraCT (identifier: 2010-023310-31; registered on 7 February 2011).
Keywords: Investigator-driven, Randomized controlled trial, Off-label antibiotics resistance, Multidrug-resistant
gram-negative bacilli, Empirical therapy, Ventilator-associated pneumoniaBackground
Infections caused by antimicrobial-resistant bacteria are a
serious public health problem, particularly those caused
by multidrug-resistant gram-negative bacilli (MDR-GNB).
The escalation of resistance is a difficult problem to man-
age; with resistance to cephalosporins first appearing,
more recently followed by carbapenems and finally the
appearance and spread of pandrug-resistant bacteria.
Acinetobacter baumannii, Pseudomonas aeruginosa and
the Enterobacteriaceae are the main MDR-GNB produ-
cing serious infections. The treatment of these infections
is difficult due to the lack of active antimicrobials [1]. In
addition, carbapenem-resistant Klebsiella pneumoniae has
become a new antibiotic resistance problem in countries
such as, Greece, Italy and Spain. This context is likely the
best example of the denominated ‘Post-Antibiotic Era’,
with relevance even in non-specialized media [2].
MDR A. baumannii has turned into one of the main
causes of hospital-acquired infection. MDR A. bauman-
nii frequently produces hospital-acquired infection and
endemic situations in intensive care units (ICUs) all over
the world [3,4]. P. aeruginosa has a similar trajectory.
Ventilator-associated pneumonia (VAP) is one of the most
common and severe hospital-acquired infections. The most
common etiologies of VAP are GNB, and among them
MDR-GNB are very frequently isolated. VAP is associated
with increased attributable mortality, length of stay and use
of resources in the ICU [5]. In addition, the risk of inappro-
priate empiric antimicrobial treatment is higher in areas
with a high prevalence of MDR-GNB. The inappropriate
empiric treatment of VAP is a risk factor for a poorer prog-
nosis [6-8]. It has been suggested that combined treatment
could help improve the results of VAP, since it broadens the
antibacterial spectrum [9]. This hypothesis has not been
confirmed in a clinical trial that compared meropenem plus
ciprofloxacin with meropenem in monotherapy [10]. In
many ICUs the proportion of resistance to all the beta-
lactams (including carbapenems) and quinolones is so high
(over 30 to 50%) [11,12] that empirical treatment with these
antimicrobials, even if combined, results in inappropriate
treatment in a high percentage of cases.
This scenario of multi-resistance has resulted in colistin
being the antimicrobial with greater in vitro activityagainst the GNB causing VAP, including the carbapenems-
resistant GNB (CR-GNB) [13]. Unfortunately, the clinical
efficacy and security of this ‘old’ antimicrobial have not
been thoroughly evaluated. The treatment of pneumonias
caused by A. baumannii and P. aeruginosa with colistin
is based on experimental studies [14,15] and clinical series,
with variable results [16-19]. According to a non-
randomized trial, colistin was less effective and safe than
beta-lactams in different infections caused by CR-GNB
[19]. However, in this study, groups were not comparable
since patients in the colistin group were older, thus coming
from healthcare facilities, with ventilator-associated support
and/or receiving inappropriate empiric treatment compared
to the group treated with beta-lactams. In contrast, other
non-randomized studies concluded that colistin has similar
efficacy and security compared to beta-lactams [16-18]. It is
important to note that the main limitation of these studies
is that none of them evaluate colistin as an empiric treat-
ment because it is only administered after the etiologic
diagnosis of the infection. Therefore, there is no suitable
clinical information on the efficacy and safety of colistin in
the empiric treatment of severe infections, including VAP,
nor randomized clinical trials that compare colistin with
carbapenems or any other beta-lactams.
Another question remaining to be solved is the opti-
mal doses of colistin for the treatment of these infec-
tions. Current recommendations are between 3 and 9
MU/day, in two or three daily administrations, based on
previous pharmacokinetic and pharmacodynamic (pK/pD)
studies conducted in patients with cystic fibrosis [8]. In a
recent study in patients with severe MDR-GNB infections
without cystic fibrosis, the use of a 9 MU/day dose was an
independent factor for positive outcome compared to
doses of 3 and 6 MU/day [6]. Recent pK/pD data in
critically ill patients recommend the administration of a
loading dose, from 9 to 12 MU, followed by doses of 4.5
MU every 12 hours in order to rapidly reach therapeutic
concentrations [20].
Infections caused by pan-resistant GNB are the most
worrisome problem in the escalation of resistance. There is
no effective empirical treatment against these infections.
The information available is from in vitro studies, experi-
mental studies and some clinical series using colistin alone
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pneumonias caused by pan-resistant A. baumannii, colistin
combined with rifampicin is superior to monotherapy with
colistin [14]. This superiority of the combined treatment
has not been demonstrated in clinical trials. Two clinical
trials have compared colistin plus rifampicin versus colistin
alone, one in patients suffering from VAP caused by A.
baumannii and the other one including patients suffering
from several infections including VAP, with disappointing
results [22,23]. In this context of multi-resistance compli-
cating the treatment of VAP, in many centers the definition
of the optimal treatment has turned into a public health
priority, as has the improvement of the methods for early
microbiological diagnosis.
Methods/Design
The MagicBullet clinical trial is designed as a phase IV,
randomized, controlled, open label, non-inferiority and
international trial to assess the safety and efficacy of colis-
tin versus meropenem in late onset VAP. This is an
investigator-driven clinical study with non-commercial
objectives within the general objectives of a global project
titled ‘Optimisation of treatment with off-patent anti-
microbial agents of ventilator-associated pneumonia
(VAP)’ funded by European public competition in the Sev-
enth Framework Program of the European Commission.
The study obtained the authorization of the Spanish Regu-
latory Authority and the Coordinating Institutional Review
Board (IRB) of Biomedical Research in Andalusia (Referral
Ethics Committee) (internal approval number 0290–10)
which gathered the approval from local ethics committees
in all the participating sites in Spain (17 sites): Virgen del
Rocío University Hospital IRB, Seville; La Fe University Hos-
pital IRB, Valencia; 12 de Octubre University Hospital IRB,
Madrid; Ciudad Real Hospital IRB, Ciudad Real; Jerez Hos-
pital IRB, Cádiz; Dr Peset University Hospital IRB, Valencia;
Puerta del Mar University Hospital IRB, Cádiz; Carlos Haya
University Hospital IRB, Málaga; A Coruña University Hos-
pital IRB, Coruña; Clinico San Carlos Hospital IRB, Madrid;
Santa Lucía University Hospital IRB, Cartagena; Marqués de
Valdecillas University Hospital IRB, Santander; Virgen de la
Victoria University Hospital IRB, Málaga; Mutua de Terrassa
IRB, Barcelona; Orense University IRB, Orense; Juan Ramón
Jiménez University Hospital IRB, Huelva; and Reina
Sof ía University Hospital IRB, Córdoba. The study also
obtained the authorization of the Greek Regulatory
Authority (72214/10-10-2012 approval number) and
National Ethics Committee (NEC Verdict number 73/12)
which gathered the approval for all the participating sites
in Greece (10 sites): ATTIKO University Hospital, Athens;
Sotiria General Hospital, Athens; G Papanikolau General
Hospital, Thessaloniki; University Hospital of Larissa,
and General Hospital of Larissa, University General
Hospital of Alexandroupoli; University General Hospitalof Heraclion, Crete; University General Hospital of Ioan-
nina; University General Hospital of Agii Anargiri, Athens;
and General Hospital Evangelismos, Athens. For Italy the
study has obtained approval from Policlinico A Gemelli
IRB, Rome; Federico II University Hospital IRB, Naples;
Molinette di Torino University Hospital IRB, Turin with
parallel authorisation from the Agenzia Italiana del
Farmaco. Three additional Italian Ethics Committees
are in the process of evaluation: AO Ospedale Niguarda
Ca Granda Milano IRB, Azienda Ospedaliera Sant’-
Andrea IRB, Rome and AOU Cisanello IRB, Pisa.
The primary objective of the study is to demonstrate
that colistin is not inferior to meropenem in the empir-
ical treatment of VAP regarding the primary endpoint
(mortality at 28 days of follow-up). As secondary end-
points, clinical healing for intention to treat in clinically
evaluable patients and comparison of microbiological ef-
ficacy are considered for both treatments arms. The
safety of treatment with colistin compared to merope-
nem in VAP will be followed for all patients.
The clinical trial is one of the work packages of a macro
project aimed at seeking solutions to MDR-GNB in-
fections, so that the samples gathered from patients in
the clinical trial (respiratory and rectal swaps samples)
are re-directed to different collaborative laboratories in
Spain (Seville, Barcelona and Coruña), France (Paris) and
Germany (Cologne), in order to assess other specific objec-
tives such as the evaluation of the impact of the antimi-
crobial treatment in the development of antimicrobial
resistance and its specific mechanism of antibiotic use on
the microbiome. Additionally two clinical centers (one in
Spain and another in Greece) also participate in a pK/pD
sub-study of colistin. A requirement of European Projects
is the participation of small to medium enterprises, two of
which are participating in this trial designing and evaluat-
ing simple, rapid and reliable procedures to determine
antibiotic susceptibility, using a DNA fluorescent staining
technique and a novel microencapsulation technology in
relevant bacteria isolated from patients with VAP. In
addition, a PCR-based technique for the early detection of
the microorganism involved in VAP, and its use to measure
the ability of antibiotic therapy to clear bacteria from the
lung, is being developed as part of the project (Figure 1).
Selection and enrollment
Patients meeting all inclusion criteria and no exclusion
criteria (detailed in Table 1) are candidates for inclusion in
the study. In brief, patients with a high suspicion of VAP
(by clinical and radiological signs), have been on mechan-
ical ventilation at least for 96 hours or less than 96 hours if
they have previously received antibiotic treatment for at
least five days and have an in-hospital stay of more than
seven days. The setting of the study will be the ICUs of
public hospitals in Spain, Italy and Greece.
Figure 1 Workflow of the general project. SME. Small medium enterprise, VAP; Ventilator associated Pneumonia, WP; work package, pK/pD:
pharmacokinetic/pharmacodinamic, MDR-GNB: multidrug resistant gram-negative bacteria.
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cific informed consent form for use in screening period
has been approved by all the 32 ethics committees for
all sites and countries involved in the trial, allowing the
prompt initiation of procedures in the moment the pa-
tient meets inclusion criteria, but having obtained con-
sent (candidate or legal representative) while they was
being evaluated.
Randomization
A 1:1 randomization system allows the assignment of treat-
ment arms; colistin or meropenem. Randomization is strati-
fied according to patient severity at the time of diagnosis of
the VAP (APACHE Acute Physiology and Chronic Health
Evaluation score ≤ or >15) and per clinical site, in order to
ensure homogeneous distribution of treatments among sites,
and according to the severity of VAP. An automatic system
integrated into the electronic case report form (eCRF) per-
mits the inclusion of patients any time of the day or on
non-working days. A copy of the randomization list is in the
enterprise that manages the CRF in case of technical prob-
lems the investigators can proceed with the inclusion of pa-
tients just contacting the CRF enterprise directly through a
phone call.
Trial intervention and control
Study drugs are commercial preparations of colistin and
meropenem. Colistin is manufactured by G.E.S; Genéricos
Españoles, Madrid, Spain. Meropenem is manufactured by
Fresenius Kabi España, Barcelona, Spain. The total amountof drugs needed for the study was purchased and specific-
ally labeled for the study following the Good Manufactur-
ing Procedures applicable in the three affected countries.
Labeling is provided in the native language for each coun-
try. Both drugs were purchased at the beginning of the
project in order to ensure the tracking of the investiga-
tional medicinal products (IMP) throughout the study as
required by Regulatory Authorities. All the authorizations
for drug management were obtained in parallel with the
clinical trial submission in the three countries and IRBs
and ethics committees affected. A specialized warehouse
located in Barcelona has been subcontracted in order to
perform labeling, distribution and supply for the three
countries involved.
Each patient will enter one of the following treatment
branches: colistin 4.5 MU intravenous loading dose as
infusions of 60 minutes followed by 3 MU administered
intravenously every eight hours in 30 minute infusions
(arm A); and meropenem 2 g administered intravenously
every eight hours in 30 minute infusions (arm B).
Besides the IMPs (colistin and meropenem) all patients
will receive levofloxacin which is considered non IMP so
that it is provided by the study site pharmacy according
the available product approved by its own providers (dose
of 500 mg every 12 hours). According to investigator cri-
teria, vancomycin or linezolid are even permitted as em-
piric treatment if methicillin-resistant Staphylococcus
aureus is suspected. Any antibiotic prescribed in the
14 days previous to randomization, and any other anti-
biotic received as concomitant medication (described in
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age ≥18 years. Renal insufficiency in substitute treatment.
≥96 hours of mechanical ventilation. Corporal weight <40 kg or >150 kg.
<96 hours of mechanical ventilation +7 days in-hospital +5 days of
antibiotic treatment.
Refractory shock or another disease that, according to the researcher,
presents a life expectancy inferior to 48 hours after recruitment.
Clinical criteria of VAP (at least one required) Patients with:
Documented fever Known or suspected CABP or viral pneumonia
An elevated total peripheral white blood cell (WBC) count
(WBC greater than 10,000/mm); or greater than 15% immature
neutrophils (bands), regardless of total peripheral WBC count;
or leukopenia with total WBC less than 4,500/mm.
Acute exacerbation of chronic bronchitis without evidence of pneumonia
New onset of expectorated or suctioned respiratory secretions
characterized by purulent appearance indicative of bacterial
pneumonia.
Tracheobronchitis
Primary lung cancer or another malignancy metastatic
to the lungs
Cystic fibrosis, bronchiectasis, HIV/AIDS, known or suspected Pneumocystis
jiroveci pneumonia, or known or suspected active tuberculosis
Immunocompromised patients; hematologic neoplasia, solid organ
transplant or congenital or acquired diseases that cause significant
immunodeficiency (examples: common variable immunodeficiency),
patients with neutropenia <500PMN/mm3.
Radiological criteria of VAP: new or progressive pulmonary infiltrate
in the thorax radiography which suggests pneumonia and with no
other probable cause.
The isolation in respiratory samples from surveillance cultures of GNB
colistin or meropenem resistant in the 7 days previous to inclusion.
Modified Clinical Pulmonary Infection Score (CPIS) >4
Respiratory secretion sample BAL or endotracheal aspirates obtained
in the 24 hours previous to the beginning of antimicrobial
treatment of the study.
Previous use of meropenem: the current use of meropenem at the time
of diagnosis is not permitted (unless this was a unique dose of 1,000 mg
as initiation of empiric treatment).
A negative pregnancy test in women of childbearing potential.
A duly signed informed consent form.
VAP: ventilator associated pneumonia, WBC: white blood cells, CPIS: Clinical Pulmonary Infection Score, BAL: bronchoalveolar lavage, CABP: Community-Acquired
Bacterial Pneumonia, HIV/AIDS: Human immunodeficiency virus/acquired immune deficiency syndrome, PMN: polymorphonuclear neutrophils, GNB: Gram-
negative bacilli.
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are obtained, will be gathered in the eCRF.
Dose adjustment is detailed in case of renal dysfunc-
tion for colistin, meropenem and levofloxacin according
to creatinine clearance. For this reason, daily renal func-
tion monitoring is performed during the duration of
antibiotic treatment. The previous use of meropenem is
permitted if there were at least three days of wash-out
until randomization in the study.
List of concomitant medication
Acetaminophen, angiotensin-converting enzyme inhibitors
(ACE), acetazolamide, allopurinol, cyclosporine, furosem-
ide, iodinated contrast, immunoglobulins, lithium, manni-
tol, non-steroidal anti-inflammatory drugs (NSAIDs),
omeprazole, penicillamine, thiazide diuretics, torsemide,
topiramate, triamterene, tacrolimus and sirolimus.
Follow-up protocol
A total of 28 days of follow-up are required for every patient
included in the study. Treatment assignment is intended forempiric treatment of the VAP, so that once the microbio-
logical results from baseline respiratory samples are ob-
tained, the investigator is free to decide the continuation of
the study drug, provided the sensibility is according to the
assigned treatment. For this reason the empiric therapy will
be adapted to the culture results. As a general rule, physi-
cians are recommended to prescribe a single antibiotic with
the narrowest spectrum which has activity against the infect-
ing organism as soon as possible. In the case of isolation of
microorganisms only sensitive to colistin and/or merope-
nem in the culture results, plus good clinical evolution of
the symptomatology, the recommendation is to maintain
the assigned treatment in the randomization process (colis-
tin or meropenem).
Regardless of changes to treatment, follow-up for pa-
tients should be performed at five time-points: baseline,
72 hours, eight days, end of treatment and 28 days. In
every visit, patients will be evaluated for clinical status,
samples collection and efficacy and safety variables in-
cluding renal monitoring functioning and adverse events
recollection. At the final evaluation, the situation of the
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results (see Table 2 for descriptions) will be collected.Samples in the study
A respiratory sample taken in the previous 24 hour
(bronchoscope with bronchoalveolar lavage or bronchial
aspirates) must be obtained before randomization and
initiation of any empiric treatment for VAP. The quan-
tity of 106 cfu/mL for the bronchial aspirate and 104 cfu/
mL for the bronchoalveolar lavage are considered as cut-
off points for positive results. Therefore, samples for the
study will be respiratory samples (bronchial aspirates if
the patient remains on mechanical ventilation, if not it
will be culture of sputum) and rectal swabs, to be re-
corded at initiation of any empiric treatment for VAP
and after 72 hours, eight days, at the end of antibiotic
treatment (if different from eight days) and 28 days of
follow-up. All study samples will be anonymized, being
identified only by the patient study code (site number
and patient number), in order to ensure that the associ-
ation with personal data is not possible. Management of
study samples is coordinated from Seville’s Instituto de
Biomedicina (IBIS), where all samples are received and
distributed to participating centers.Outcome measures
The primary efficacy endpoint will be assessed in all pa-
tients with evaluable microbiological diagnosis of pneu-
monia by MITT modified intention to treat analysis
(patients with culture confirmed in the relevant sample
and who have received at least one dose of the experi-
mental drug or control), by comparing mortality at
28 days between each group.
The secondary variables will include: evaluation of
clinical cure in the clinically evaluable population; evalu-
ation of microbiological cure in the microbiologically
evaluable population; evaluation of cure, failure or un-
determined result at the end of the treatment; evaluation
of cure, failure or relapse at the end of follow-up and
safety evaluation in all the patients who received at least
one antibiotic dose during the 28 days of follow-up.Table 2 Description of secondary variables
Definitions Clinical efficacy Microbiological ef
Cure Complete resolution of all signs and
symptoms of pneumonia.
Eradication of the b
associated pneumo
Failure Persistence or progression of signs and
symptoms.




Recurrence of signs, symptoms and/or




evaluation and isolaSafety will be evaluated in patients who receive any of
the drugs of the study via an intention-to-treat analysis.
Any adverse event occurring from the informed consent
form signature to 28 days after the last dose of study
medication will be recorded.
Sample size calculation
The primary efficacy analysis assessed the non-
inferiority of the mortality rate of intravenous colistin
plus levofloxacin compared to intravenous meropenem
plus levofloxacin in the MITT population. Non-
inferiority of colistin is concluded if the lower limit of
the two-sided 95% confidence interval for the difference
in mortality rates (colistin minus meropenem) is ≤10%.
In order to achieve a power of 80% to reject the null
hypothesis with a significance level of 5%, assuming as
stated in previous studies that the survival rate is 80%
with standard treatment [11], and the same with experi-
mental treatment, with a non-inferiority limit of ≤10%,
198 patients are needed in each group. Taking into
account that microbiological documentation of VAP is
obtained in approximately 80% of the episodes, and
therefore about 20% of randomized patients will not
have a microbiological diagnosis and will not be useful
for evaluation of effectiveness, this requires a 25% in-
crease in sample size. This increases the sample size of
intention-to-treat patients included to a total number of
496.
Statistical analysis
A safety evaluation will be performed in all the patients
who have received at least one study treatment drug, in-
dependent of reaching the microbiological diagnosis.
The efficacy evaluation will be performed in every pa-
tient who receive at least one study treatment drug, per
MITT. The primary efficacy will first be valued by
means of comparison of mortality at 28 days, and sec-
ondary variables of efficacy will be valued by means of
clinical and microbiological cure.
The clinical evaluation by modified intention to treat
(MITT) will be realized in the population that fulfills the
inclusion criteria and receives at least one dose of theficacy Timeframe
acterium causing ventilator-
nia during the treatment.
At 28 days of follow-up.
acterium causing ventilator-
nia during the treatment.
At 28 days of follow-up.
, symptoms or new radiographic
onia present in the last
tion of the initial pathogen.
At 28 days of follow-up.
At any time after treatment finalization
to end of follow-up.
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include those that fulfill the inclusion criteria, who have
received the intravenous treatment and with evaluation
response data available at the end of the treatment.
Safety and adverse event reporting
In order to meet all the legal requisitions applicable in
clinical trials, a pharmacovigilance system has been im-
plemented for registering, reporting and communicating
all adverse events occurring within the patient included
in the clinical trial.
Every study team is trained during the site initiation
visit on the definitions of adverse events and rules for
communication. Any adverse event related or not with
the study medication has to be gathered in the eCRF
which contains a specific pharmacovigilance module.
Only serious adverse events (SAE) are to be completed
with more detailed information, such as SAE description
(according to MedDra terminology), date of onset and
resolution, severity, assessment of causality to study
medication, action taken and other concomitant medica-
tion and/or procedures. Initial and follow-up communi-
cation until resolution is asked of the sites.
The SAEs form is centralized in the CTU-HUVR, whose
personnel are responsible for the reception (by fax or email
communication), registering and resolution of queries to
the sites. A safety medical monitor will assess the SAEs
form in order to evaluate if the information is to be com-
municated to regulatory authorities, ethics committees and
investigators, following Good Clinical Practices rules pro-
vided for the presence of a serious unexpected adverse
event (SUSAR). In cases where a communication through
EudraVigilance system is foreseen for any of the three
countries this is performed by the CTU-HUVR personnel
after the complete information confirmed with the study
site and the generation of CIOMS form (Council for Inter-
national Organizations of Medical Sciences form). Annual
safety reports are issued with all the safety information in
the study being reported to regulatory authorities and eth-
ics committees (in case of Italy and Greece through the
subcontracted contract research organizations (CROs)).
The safety medical monitor is responsible for any update
in the safety information of the IMPs.
Study organization
The clinical trial is being performed in 32 reference hospi-
tals in Spain (16 centers), Greece (10 centers) and Italy
(6 centers). The coordinating trial site is located in the
same public hospital leading the study, CTU-HUVR, and
is responsible for the whole coordination of the study and
all the sites involved, submitting the administrative autho-
rizations of the study, handling regulatory affairs, contact
with ethics committees and response, drug management,
labeling and distribution of the IMPs, safety monitoringand pharmacovigilance responsibilities of the sponsor, as
well as logistic coordination and providing a contact point
for all the 32 clinical teams participating in the study and
monitoring activities.
CTU-HUVR acts as a delegation figure of the sponsor
(FISEVI, Fundación Pública Andaluza para la Gestión de
la Investigación en Salud de Sevilla, managing foundation
for research in Seville) in relevant activities involved in a
multicenter and international trials. In order to ensure the
quality of all the activities and resolving specific country as-
pects related to the approval or local administrative require-
ments in Italy and Greece, two CROs are subcontracted.
Monitoring activities in Spain are performed by clinical re-
search associates (CRAs) pertaining to the Spanish Clinical
Trial Network in public hospitals. CTU-HUVR is in close
contact with the scientific coordinators of the study, acting
accordingly and in a parallel manner so that any decision
taken is previously consulted with the study coordination
team. Moreover, a project management team at FISEVI is
in charge of financial and contractual aspects of the project,
as well as general communication and the dissemination
plan. A webpage for the study is publically available [24],
with specific content requiring login and being password-
protected, including the eCRF for the clinical trial, of which
managing and updating is the responsibility of the project
management team. IBIS-HUVR is in charge of the manage-
ment of the entire number of samples, including reception,
classification and delivery to collaborating laboratories.
Data and safety monitoring
Remote control of data will be performed through data
entry in a weekly fashion by a central CTA working in the
CTU-HUVR. Any lack of completion or detected mistake
will be promptly communicated to the local monitor (sub-
contracted CRO for Italy and Greece, and Spanish Clinical
Trial network for Spain) in order to be completed or cor-
rected so data are the most accurate and updated as pos-
sible. Besides this one site initiation visit per site which
provides specific training for the study, monitoring visits
(number depending on recruitment rhythm or problems
detected) and close-out visit to each site will be performed
according to the monitoring plan approved for the study,
which details the data to be controlled with source docu-
ments, and procedures for the monitoring and reporting
of monitoring visits to the CTU-HUVR.
A Data and Safety Monitoring Board (DSMB) is fore-
seen when 50% of the sample size is recruited. The
DSMB is charged with monitoring the accumulating
data from the clinical trial to detect and report early evi-
dence of pre-specified or unanticipated benefit or harm
to trial participants that may be attributable to one of
the treatments under evaluation. The DSMB will con-
duct an independent objective review of all accumulated
data from the clinical trial in such a manner as to
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search effort. Based on this review, the DSMB shall ad-
vise the sponsor on the appropriateness of continuing
the clinical trial as designed. In order to duly perform its
responsibilities, the DSMB will:
1. review the research protocol and plans for data and
safety monitoring;
2. evaluate the progress of the interventional trial,
including periodic assessments of data quality and
timelines, participant recruitment, accrual and
retention, participant risk versus benefit,
performance of trial sites and other factors that can
affect study outcome;
3. monitoring should also consider factors external to
the study when interpreting the data, such as
scientific or therapeutic developments that may have
an impact on the safety of the participants or the
ethics of the study;
4. make recommendations to the sponsor, IRB and
investigators concerning continuation or conclusion
of the trial; and
5. protect the confidentiality of the trial data and the
results of monitoring.
The MagicBullet DSMB monitoring outcome data will
be external to the group. Monitoring activities will be
conducted by independent experts in all scientific disci-
plines needed to interpret the data and ensure patient
safety. Otherwise, clinical trial experts, biostatisticians,
bioethicists and clinicians knowledgeable about the dis-
ease and treatment under study should be available if
warranted.
Ethical, deontological and regulatory considerations
The clinical trial will be carried out according to the
principles of the Declaration of Helsinki, and according
to the legal norm directive 2001/20/EC of the European
Parliament and of the council of 4 April 2001 on the ap-
proximation of the laws, regulations and administrative
provisions of the Member States relating to the imple-
mentation of Good Clinical Practice in the conduct of
clinical trials on medicinal products for human use.
The trial was not started at any site until having ob-
tained approval of the Ethic committess, conformity of
the Directors of the institutions and the authorization of
the Spanish Agency of Drugs and Medical Devices
(AEMPS, Agencia Española del Medicamento y Produc-
tos Sanitarios), the Italian Medicines Agency (AIFA,
Agenzia Italiana del Farmaco) and Greek National
Organization for Medicines (EOF, Ethnikos Organismos
Farmakon). The confidentiality of records that could
identify subjects in the MagicBullet trial will be pro-
tected in accordance with the European Union Directive2001/20/EC and as a result of the Good Clinical Practice
inspections, in accordance with the applicable national
and international requirements and any specific require-
ment related to data protection in each participating
country. All the laws that legislate for the control and
protection of personal information will be carefully
followed. The identity of patients will not be disclosed in
the eCRF; names will be replaced by an alphanumerical
code and any material related with the trial, such as
samples, will be identified in the same way so that no
personal information could be revealed.
As long as the MagicBullet trial will be performed in
ICUs, the sort of patients to be included in the trial
could be in emergency situations. In cases when prior
consent of the subject is not possible, the consent of the
subject’s legally acceptable representative, if present, will
be requested. A consent form specifically designed to
the subject’s legally acceptable representative will be pro-
vided with documented approval or favorable opinion by
the IRB or EC, to protect the rights, safety and wellbeing
of the subject and to ensure compliance with applicable
regulatory requirements. The patient or their legal repre-
sentative must sign a document of informed consent ap-
proved by the Ethics Committees as inclusion criteria
for the study. Moreover, due to the specific situation of
ICU patients, an informed consent form will be offered
in the screening period to the representative or relative.
This screening period informed consent form has been
approved by the Ethics Committees and it is intended to
have the possibility of recruitment in case the represen-
tative is not easily available (provided the patient accom-
plishes all the criteria), having the confirmation of the
willingness for participation in the trial when the patient
is being evaluated.
The Consolidated Standards for Reporting Trials
(CONSORT) guidelines will be followed for the report-
ing of results to any scientific journal or event.
Discussion
MagicBullet has put in motion one of the first investigator-
driven clinical trials of off-patent antibiotics funded by the
European Union. In order to initiate this independent clin-
ical trial without the support of the pharmaceutical indus-
try, many tasks had to be developed: selection of the
participating hospitals, approval of the trial by the ethics
committees of each hospital, authorization of the study
and drug management system from the regulatory author-
ities in the three countries, contracting of two CROs and
public procurements for the provision of the eCRF and
website, study drugs, transportation of the biological sam-
ples and drug handling. For the implementation of all these
tasks, great effort was devoted, as international coordin-
ation and resources available in public settings are not
comparable with the pharmacy industry or private sponsors
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reasons, adding to the difficulties of clinical trials whose re-
cruitment periods are to be extended in most cases, despite
the efforts devoted to increase recruitment as described in
the literature [25].
This is a multidisciplinary research consortium com-
posed of clinicians with expertise in the diagnosis and
treatment of infections due to MDR-GNB; microbiolo-
gists expert in the study of the genetics, biochemical and
molecular bases of bacterial resistance to antimicrobials;
basic researchers expert in human studies and experi-
mental infections by MDR-GNB; researchers expert in
industrial research and development projects and ex-
perts in clinical trial operations and pharmacovigilance.
Through a complete non-commercial network (basically
public hospitals and academics) we have designed, have
obtained European competitive funding for, and have set
up an independent investigator-driven clinical trial
among three countries without any pharmaceutical sup-
port in order to identify the optimal treatment option
for VAP caused by MD-GNB. Moreover, we are contrib-
uting to scientific calls such as ‘New Drugs for Bad Bugs’
(ND4BB) [26], on which academic organizations are ask-
ing for clinical trials performance to address the problem
of antibiotics depletion.
Scientific societies such as the Infectious Disease Soci-
ety of America (IDSA) and the Food and Drug Adminis-
tration (FDA) consider the non-inferiority design for
clinical trials of patients with VAP to be appropriate,
using as the primary indicator the outcome of mortality
at 30 days of follow-up, and using a non-inferiority abso-
lute margin of 10%. The MagicBullet trial meets each of
these criteria. Scientific societies also recommend that
the effectiveness evaluation is performed in the popula-
tion with microbiological diagnosis and per intention-to-
treat analysis. In the MagicBullet protocol, the efficacy
evaluation was initially planned to be performed with
patients with clinical diagnosis (clinical and radiological)
and who were part of the intention-to-treat population.
This design has been used for the last antimicrobial
approval, doripenem, for indication of VAP [27]. In
order to use the same evaluation criteria for efficacy
that has been proposed by the FDA and scientific
societies, evaluation criteria for effectiveness were
modified for efficacy assessment, considering microbio-
logically evaluable patients per intention to treat (pa-
tients with confirmed culture in respiratory sample and
who had received at least one dose of experimental or
control drug).
Colistin and meropenem are both off-patent antimi-
crobials. Meropenem is considered as the optimal treat-
ment for GNB causing VAP infections. Colistin, the
experimental treatment, has been commercialized for
more than 60 years. Up to this project, no randomizedclinical trial including such a number of patients with
colistin has been carried out.Trial status
The sample size recruited to date is 178 patients, ac-
counting for 36% of the sample size (95 in Spain, 36 in
Italy and 47 in Greece). The study has been active since
May 2012, the date on which the first patient was in-
cluded. Due to several bureaucratic and local aspects,
only recently have almost the total number of sites been
active to recruit patients (30 sites now officially opened).
The non-commercial nature of this study, entirely per-
formed by public institutions, has faced several impedi-
ments which have delayed the activation of clinical sites.
Problems such as local administration and approvals,
organization of international deliveries or internal
organization have caused one year of delay according to
the initial planning. During this time we have suffered
administrative delays in ethics committees in Italy, de-
lays due to general strikes in Greece and non-reasonable
delays due to excessive bureaucracy.
The initial recruitment period was two years, but the
different initiation dates in Spain, Italy and Greece and
the current activation of the majority of sites, as well as
the results obtained by laboratories and the effective
recruitment of 36% of the sample size, has permitted
the submission of the extension of the project to the
European Commission. After the extension, the project
will have active recruitment until November 2015, a
time we consider it feasible to achieve the expected
sample size (495) by, or at least the sample size needed
to evaluate efficacy (396).
Activities such as monthly conferences with the active
sites, constant communication with investigators and
CROs, updated information via monthly newsletters,
other specific communications and the external and in-
ternal parts of the website of the project have been a key
part of the coordination activity. In parallel, onsite and
phone meetings have taken place between the CTU-
HUVR and the monitors of the clinical trial in order to
enhance recruitment at a local level. Recruitment stimu-
lation through personal communication from the study
leader, who is responsible for the clinical trial, has been
a key factor in the work carried out by the coordination
of the clinical trial since its beginning, and will continue
in the future in order to achieve the sample size needed
for the study.
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